If successful, non-invasive method could transform detection and treatment outcomesContinue reading
Author Archive: AZBio
Exact Sciences to Acquire Ashion Analytics and Enter Research Collaboration with City of Hope’s Genomic Institute, TGen
Provides Access to Industry-Leading Sequencing Lab and Plans for 10-Year Partnership with National Cancer Research Leaders
Arizona Board of Regents announces José Luis Cruz as Northern Arizona University presidential finalist
The Arizona Board of Regents announced today that José Luis Cruz, Ph.D. is the finalist for the position of the 17th president of Northern Arizona University.Continue reading
UArizona Startup GenetiRate Acquired by Aquaculture Biotechnology Company
TUCSON, Ariz. – University of Arizona startup GenetiRate has been acquired by biotechnology company IMV Technologies.Continue reading
AZBio Elects 2020 Officers and Welcomes New Board Members
The Arizona Bioindustry Association, Inc. (AZBio) Board of Directors has elected its 2021 officers and welcomes seven new board members in 2021. Continue reading
eNAMPT, the Inflammation-Regulatory Protein Specifically Targeted by Aqualung Therapeutic’s Monoclonal Antibody ALT-100, is now Tightly Linked to Outcomes in COVID-19 Infected Patients
TUCSON, AZ / ACCESSWIRE / February 11, 2021 / Several recent publications have now highlighted the involvement of extracellular nicotinamide phosphoribosyltransferase (eNAMPT) in the pathobiology of SARS-CoV-2 infection.
Botanisol Analytics and Ocean Insight Introduce First Laser Virus Screener
Free Resource for Businesses – Pandemic Response, Recovery and Planning
This handbook for businesses on pandemic response lessons learned with some considerations businesses can look at on re-opening, vaccine hesitancy, preparing for the next pandemic now, etc. was developed by the Northeast Business Group on Health. Continue reading
Coronavirus (COVID-19) Update: FDA Authorizes Monoclonal Antibody for Treatment of COVID-19
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the investigational monoclonal antibody therapy bamlanivimab for the treatment of mild-to-moderate COVID-19 in adult and pediatric patients. Bamlanivimab is authorized for patients with positive results of direct SARS-CoV-2 viral testing who are 12 years of age and older weighing at least 40 kilograms (about 88 pounds), and who are at high risk for progressing to severe COVID-19 and/or hospitalization. This includes those who are 65 years of age or older, or who have certain chronic medical conditions.Continue reading
Final Steel Beam Tops Off The Refinery Building at the UA Tech Park at The Bridges
TUCSON, Ariz.– The steel frame and concrete floors are coming to completion at The Refinery. The final beam of The Refinery was placed, topping off the steel framework for the 120,000 square foot structure. The Refinery is the kickoff building to the new UA Tech Park at The Bridges, an extension campus birthed from the success of the UA Tech Park near Interstate 10 and Rita Road. Continue reading